Assessment
sleep stage, cataplexy, g).On
SECONDARY, CATAPLEXY
This post hoc analysis evaluated primary and secondary endpoints from the REST-ON study in 2 separate subgroups: participants with NT1 and those with NT2. Coprimary efficacy endpoints were the change from baseline in MWT, CGI-I, and weekly cataplexy attacks (not applicable for this analysis). Secondary endpoints included change from baseline in the (1) number of sleep stage shifts, (2) number of nocturnal arousals, (3) patient-reported quality of sleep, (4) patient-reported refreshing nature of sleep, and (5) patient-reported ESS score. Both primary and secondary efficacy assessments were recorded at baseline and weeks 3 (6 g), 8 (7.5 g), and 13 (9 g).On the test day, mean sleep latency on the MWT was averaged over five 30-minute trials. Each trial was terminated immediately after sleep onset or after 30 minutes if no sleep onset occurred [